Your browser doesn't support javascript.
loading
The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy.
Lisencu, Lorena Alexandra; Roman, Andrei; Visan, Simona; Bonci, Eduard-Alexandru; Pașca, Andrei; Grigorescu, Emilia; Mustea, Elena; Cismaru, Andrei; Irimie, Alexandru; Lisencu, Cosmin; Balacescu, Loredana; Balacescu, Ovidiu; Tudoran, Oana.
Afiliação
  • Lisencu LA; Department of Oncological Surgery and Gynecological Oncology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
  • Roman A; Department of Radiology, The Oncology Institute "Prof. Dr. Ion Chiricuța", 400015 Cluj-Napoca, Romania.
  • Visan S; Department of Genetics, Genomics and Experimental Pathology, The Oncology Institute "Prof. Dr. Ion Chiricuța", 400015 Cluj-Napoca, Romania.
  • Bonci EA; Department of Oncological Surgery and Gynecological Oncology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
  • Pașca A; Department of Surgical Oncology, The Oncology Institute "Prof. Dr. Ion Chiricuța", 400015 Cluj-Napoca, Romania.
  • Grigorescu E; Department of Oncological Surgery and Gynecological Oncology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
  • Mustea E; Department of Surgical Oncology, The Oncology Institute "Prof. Dr. Ion Chiricuța", 400015 Cluj-Napoca, Romania.
  • Cismaru A; Department of Pathological Anatomy, County Emergency Hospital, 400347 Cluj-Napoca, Romania.
  • Irimie A; Department of Pathological Anatomy, County Emergency Hospital, 400347 Cluj-Napoca, Romania.
  • Lisencu C; Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy "Iuliu Hatieganu", 400037 Cluj-Napoca, Romania.
  • Balacescu L; Department of Oncological Surgery and Gynecological Oncology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
  • Balacescu O; Department of Surgical Oncology, The Oncology Institute "Prof. Dr. Ion Chiricuța", 400015 Cluj-Napoca, Romania.
  • Tudoran O; Department of Oncological Surgery and Gynecological Oncology, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Medicina (Kaunas) ; 58(10)2022 Oct 20.
Article em En | MEDLINE | ID: mdl-36295655
ABSTRACT
Background and

Objectives:

Prediction of response to therapy remains a continuing challenge in treating breast cancer, especially for identifying molecular tissue markers that best characterize resistant tumours. Microribonucleic acids (miRNA), known as master modulators of tumour phenotype, could be helpful candidates for predicting drug resistance. We aimed to assess the association of miR-375-3p, miR-210-3p and let-7e-5p in breast cancer tissues with pathological response to neoadjuvant therapy (NAT) and clinicopathological data. Material and

methods:

Sixty female patients diagnosed with invasive breast cancer at The Oncology Institute "Ion Chiricuța", Cluj-Napoca, Romania (IOCN) were included in this study. Before patients received any treatment, fresh breast tissue biopsies were collected through core biopsy under echographic guidance and processed for total RNA extraction and miRNA quantification. The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) database was used as an independent external validation cohort.

Results:

miR-375-3p expression was associated with more differentiated tumours, hormone receptor presence and lymphatic invasion. According to the Miller-Payne system, a higher miR-375-3p expression was calculated for patients that presented with intermediate versus (vs.) no pathological response. Higher miR-210-3p expression was associated with an improved response to NAT in both Miller-Payne and RCB evaluation systems. Several druggable mRNA targets were correlated with miR-375-3p and miR-210-3p expression, with upstream analysis using the IPA knowledge base revealing a list of possible chemical and biological targeting drugs. Regarding let-7e-5p, no significant association was noticed with any of the analysed clinicopathological data.

Conclusions:

Our results suggest that tumours with higher levels of miR-375-3p are more sensitive to neoadjuvant therapy compared to resistant tumours and that higher miR-210-3p expression in responsive tumours could indicate an excellent pathological response.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Neoplasias Tipo de estudo: Guideline Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Neoplasias Tipo de estudo: Guideline Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article